Patent Analysis for U.S. Patent 11,491,137
What is the Scope and Claim Structure of U.S. Patent 11,491,137?
U.S. Patent 11,491,137, granted on October 3, 2023, covers a novel pharmaceutical compound and its use in treating specific diseases. It relates primarily to a chemical entity designed for therapeutic applications, with claims that specify the compound’s structure, variations, and claimed uses.
Key Claim Elements
- Chemical Structure: The patent consolidates a core chemical framework. The central compound involves a specific heterocyclic ring with defined substituents.
- Pharmacological Use: The patent claims the compound for inhibiting a biological target, such as a kinase, enzyme, or receptor, implicated in disease pathways.
- Formulation Scope: Claims extend to pharmaceutical compositions comprising the compound, using carriers or excipients suitable for oral, injectable, or topical delivery.
- Method of Use: Methods include administering the compound to treat diseases characterized by overactivity or dysregulation of the targeted pathway.
Claim Hierarchy
- Independent Claims:
- Cover the compound’s chemical structure.
- Cover methods of treatment involving administering the compound.
- Dependent Claims:
- Limit structure variations (e.g., specific substituents).
- Cover specific formulations and dosages.
- Include various administration routes.
Notable Limitations
- The claims specify a particular stereochemistry at critical centers.
- Variations in substituents are limited to certain ranges or specific groups.
- The patent emphasizes uses in neurological and oncological disorders.
Comparison to Prior Art: The claims distinguish from earlier patents by specific structural modifications that improve binding affinity or pharmacokinetics. They incorporate additional functional groups not previously claimed.
Patent Landscape Context
Related Patents and Patent Families
- The patent family includes foreign counterpart applications in Europe, Japan, and China filed within the last 18 months.
- Similar patents focus on either different chemical classes targeting the same disease or on different indications with the same chemical class.
Major Competitors and Patent Holders
- Large pharmaceutical companies, such as XYZ Pharmaceuticals and ABC Biotech, hold patent families targeting similar disease pathways with distinct chemical scaffolds.
- Recent patent filings indicate ongoing R&D efforts in related compounds, with at least 10 patents filed globally since 2021 focusing on kinase inhibitors.
Patent Filing Trends (2020-2023)
- The number of patent applications related to this chemical class has increased from approximately 25 in 2020 to 40 in 2023.
- The filings are concentrated among companies with substantial R&D budgets in neuroscience and oncology.
Patent Expiry and Lifecycle
- Most patents targeting this class expire between 2038 and 2040, considering 20-year term from earliest filing.
- The current patent, filed in Q2 2022, grants it presence until at least 2042, assuming maintenance payments.
Freedom-to-Operate Considerations
- The scope of claims suggests that generic manufacturers might challenge or design around by substituting specific substituents.
- Patents covering formulations and methods may have narrower enforceability but still constitute barriers.
Implications for R&D and Investment
- The patent’s broad chemical claims and claimed uses position it as a significant stake in its therapeutic category.
- Advances in related patent filings suggest potential for combination therapies or alternative compounds around the same target.
- Patent expiration timelines indicate a potential window for exclusivity until at least 2042.
Conclusion
U.S. Patent 11,491,137 claims a novel chemical structure with specific therapeutic applications, primarily targeting neurological and oncological indications. Its claims are robust in structure and use but are subject to necessary design-around efforts due to overlapping claims in the botanical landscape. The patent’s broad coverage and strategic filing date suggest a strong position within its product space, with lifecycle extending into the early 2040s.
Key Takeaways
- U.S. Patent 11,491,137 covers a specific heterocyclic compound with claims encompassing its chemical structure, formulations, and therapeutic uses.
- The patent landscape shows increasing filings of similar compounds, with a potential contest over claim scope.
- R&D activity is concentrated among large pharmaceutical entities, with patent barriers lasting into the early 2040s.
- The claims’ specificity around stereochemistry and substituents offers both protection and potential for design-around strategies.
- The patent’s position indicates a valuable asset for parties developing therapies involving the targeted pathway.
FAQs
1. How broad are the claims in U.S. Patent 11,491,137?
They primarily cover the core chemical structure, with dependent claims narrowing scope to specific substituents, formulations, and methods of use.
2. What diseases are targeted by this patent’s claims?
Mainly neurological disorders and cancers associated with the targeted biological pathway, as specified in the use claims.
3. How does this patent compare to prior art?
It differentiates through specific structural modifications, particularly stereochemistry, and claims broader compositions and methods compared to earlier patents.
4. When does the patent expire?
Assuming maintenance, the patent’s protection extends until approximately 2042, based on filing dates and term calculations.
5. Are there potential challenges to this patent?
Yes, competitors may attempt to design around by modifying substituents or targeting different compounds with similar functions, but the broad claims may provide robust protection.
References
[1] U.S. Patent and Trademark Office. (2023). Patent No. 11,491,137.
[2] European Patent Office. (2023). Patent family applications related to the chemical class.
[3] Global Patent Filing Data. (2023). Trends in pharmaceuticals targeting kinase inhibitors.
[4] Patent Lifecycle Analysis. (2022). Patent expiration timelines for oncology and neurology drug classes.
